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E. coli NfsA: an alternative nitroreductase for prodrug activation
gene therapy in combination with CB1954
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1Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK; 2School of Biosciences, University of Birmingham,
Birmingham, UK; 3Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand
Prodrug activation gene therapy is a developing approach to cancer treatment, whereby prodrug-activating enzymes are expressed in
tumour cells. After administration of a non-toxic prodrug, its conversion to cytotoxic metabolites directly kills tumour cells expressing
the activating enzyme, whereas the local spread of activated metabolites can kill nearby cells lacking the enzyme (bystander cell
killing). One promising combination that has entered clinical trials uses the nitroreductase NfsB from Escherichia coli to activate the
prodrug, CB1954, to a potent bifunctional alkylating agent. NfsA, the major E. coli nitroreductase, has greater activity with nitrofuran
antibiotics, but it has not been compared in the past with NfsB for the activation of CB1954. We show superior in vitro kinetics of
CB1954 activation by NfsA using the NADPH cofactor, and show that the expression of NfsA in bacterial or human cells results in a
3.5- to 8-fold greater sensitivity to CB1954, relative to NfsB. Although NfsB reduces either the 2-NO2 or 4-NO2 positions of
CB1954 in an equimolar ratio, we show that NfsA preferentially reduces the 2-NO2 group, which leads to a greater bystander effect
with cells expressing NfsA than with NfsB. NfsA is also more effective than NfsB for cell sensitisation to nitrofurans and to a selection
of alternative, dinitrobenzamide mustard (DNBM) prodrugs.
British Journal of Cancer (2009) 100, 1903–1911. doi:10.1038/sj.bjc.6605094 www.bjcancer.com
Published online 19 May 2009
& 2009 Cancer Research UK








































Gene-directed enzyme prodrug therapy (GDEPT) is a developing
strategy for cancer treatment, involving delivery to tumour cells of
an exogenous gene, encoding an enzyme that can convert a non-
toxic prodrug into cytotoxic products. In principle, local genera-
tion of highly reactive cytotoxins within the cancer cells allows
optimal therapeutic effect, whereas systemic toxicity remains lower
than with conventional chemotherapy (McNeish et al, 1997;
Niculescu-Duvaz and Springer, 2005; Russell and Khatri, 2006).
As specific gene delivery to all tumour cells seems unattainable
using current methods, the ability of an activated prodrug to
spread locally from cell to cell is considered an essential feature for
a successful GDEPT system. It allows tumour cells that have
escaped gene transfer to be killed as a result of prodrug activation
in nearby cells that express the activating enzyme. This is known as
the ‘bystander effect’ (Freeman et al, 1993).
CB1954 (5-[aziridin-1-yl]-2,4-dinitrobenzamide) is a prodrug,
which is converted from a weak, monofunctional alkylating agent
to a potent bifunctional alkylating agent upon nitroreduction
(Knox et al, 1988, 1991; Friedlos et al, 1992). Anlezark et al (1992)
reported that the nitroreductase encoded by the nfsB gene of
Escherichia coli could activate CB1954, leading to the initial
adoption of this enzyme for use with CB1954 in GDEPT (Anlezark
et al, 1992; Bridgewater et al, 1995; Grove et al, 1999; Searle et al,
2004). The expression of NfsB in cancer cells using replication-
defective retrovirus or adenovirus vectors was shown to confer
greatly increased sensitivity to CB1954, and anti-tumour activity
was shown in vivo (McNeish et al, 1998; Djeha et al, 2000, 2001;
Weedon et al, 2000). After the initial phase I clinical trials of
CB1954 alone (Chung-Faye et al, 2001), and of a replication-
defective adenovirus expressing NfsB (CTL102) (Palmer et al,
2004), the combination has been tested in a phase I/II trial in
patients with prostate cancer. A decline in serum levels of prostate
specific antigen in some patients suggests anti-tumour activity
(Patel et al, 2009); however, greater efficacy is desirable.
NfsB is a homodimeric flavoenzyme which can use either NADH
or NADPH to reduce the tightly bound FMN; after dissociation of
the NAD(P)þ ; a variety of nitroaromatic or quinone substrates can
be reduced in a second reaction step (Anlezark et al, 1992;
Lovering et al, 2001; Race et al, 2005). The published Km for NfsB
nitroreductase with CB1954 is 862 mM (Anlezark et al, 1992), which
is considerably higher than its peak serum concentration
achievable in humans (5–10 mM) (Chung-Faye et al, 2001). Thus,
the activation of CB1954 by NfsB in vivo will be very inefficient,
justifying the consideration of alternative enzymes (Anlezark et al,
2002). NfsB was originally identified through its role in bacterial
sensitivity to nitrofuran antibiotics (Sastry and Jayaraman, 1984).
Selection of E. coli for nitrofurazone resistance leads first to
mutations in the major nitroreductase gene, nfsA (Whiteway et al,
1998), and only subsequently in nfsB. Alignment of the amino acid
sequences shows only 28 identical and 32 conserved residues out
of the 242 or 217 residues of NfsA and NfsB, respectively, and
antibodies specific for NfsB do not cross-react with NfsA
(unpublished results). The two enzymes share many structural
features, including a 5-stranded anti-parallel b-sheet core and
surrounding a-helices, with the two active sites occupying clefts at
the dimer interface and presenting the re-face of the FMN
isoalloxazine ring towards the substrate pocket (Kobori et al,
2001; Lovering et al, 2001). Although some residues around the
active site are conserved, the active site of NfsA is more open than
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that of NfsB, an observation that contributed to our decision to
investigate its activity with CB1954 and other prodrugs. Kinetic
studies of the purified enzymes showed that NfsA has a two- to
three-fold greater activity with nitrofurazone and several other
nitroaromatic substrates, compared with NfsB (Zenno et al, 1996).
The report that NfsA has a marked preference for the cofactor
NADPH (Zenno et al, 1996) suggested that this enzyme may have
been overlooked in the initial isolation of NfsB for the reduction of
CB1954, which used NADH as a cofactor (Anlezark et al, 1992).
One study has shown that NfsA is capable of CB1954 activation
(Barak et al, 2006); however, to our knowledge, no earlier study
has compared the activities of NfsA and NfsB with CB1954. In this
study, we compare the ability of these two E. coli nitroreductases to
sensitise cells to CB1954 and a selection of other prodrugs. We also
compare their kinetics of CB1954 activation in vitro, and show that
NfsA preferentially reduces the 2-NO2 group of CB1954, resulting
in an improved bystander cell killing. Overall, the results suggest
that NfsA could have advantages over NfsB for use in GDEPT with
CB1954 or several other nitroaromatic prodrugs.
MATERIALS AND METHODS
Bacterial expression vector construction
The nfsA gene was amplified by PCR from E. coli DH5a genomic
DNA using primers PS1296C GGAATTCATATGACGCCAACCAT
TGAACTTATTTGTG and PS1296D GTGGATCCTATTAGCGCGT
CGCCCAACCCTG, digested with Nde I and Bam HI (underlined)
and inserted between these sites downstream of the tac promoter
in plasmid pJG12B1 (Grove et al, 2003), producing pSV036B9. The
same Nde I to Bam HI fragment was also inserted into pET24c
(Novagen, Madison, WI, USA), making pPS1341A1. The Sfi I
fragment containing the nfsA gene and the upstream ribosome
binding site from pSV036B9 was ligated downstream of the tac
promoter into the bacteriophage l-vector lJG3J1 (Grove et al,
2003), producing lSV054, which was packaged and used to
generate lysogens of the E. coli strain, UT5600 (nfsB), as before
(Grove et al, 2003).
Bacterial prodrug susceptibility assay
Cultures of E. coli UT5600 lysogens carrying lSV054, the empty
vector lJG3J1 or the same vector expressing NfsB (lJG16C2)
were grown to mid log phase in a liquid medium, before dilution
and spreading onto agar plates containing a range of CB1954
concentrations, essentially as described (Grove et al, 2003). Colonies
were counted after 24 h of incubation at 371C. The plating efficiency
at each prodrug concentration was calculated as a percentage of the
number of colonies obtained in the absence of prodrug.
Protein purification
NfsB was expressed in the E. coli strain BL21(lDE3) transformed with
a pET11c plasmid containing the nfsB gene and purified as described
(Lovering et al, 2001). NfsA was purified from E. coli BL21(lDE3)
transformed with plasmid pPS1341A1, using a method based on that
used for NfsB, but the initial supernatant after sonication was
fractionated using 30–70% NH4SO4. The 70% NH4SO4 precipitate
was dissolved and fractionated on phenyl sepharose and Q-sepharose
columns as for NfsB (Lovering et al, 2001).
Steady-state enzyme kinetic studies
Reactions were performed in 10 mM Tris pH 7.0, 5% DMSO at
251C, initiated by the addition of a small volume of cold, dilute
enzyme (typically 10 nM), and the initial rates of formation of the
2- and 4-hydroxylamine products of CB1954 were monitored
spectroscopically at 420 nm, a wavelength at which both products
have the same molar absorbance (1200 M1cm1). The data were fitted
to Michaelis–Menten curves using SigmaPlot 10 (Systat Software Inc.,
Richmond, CA, USA) as described earlier (Race et al, 2007).
HPLC analysis of CB1954 reaction products
Reaction mixtures containing 200mM CB1954, 1 mM NAD(P)H and
1 mM NfsA or NfsB in 10 mM Tris pH 7.0, 5% DMSO were incubated
at room temperature for 5 min, before separation by semi-
preparative reverse-phase HPLC as described earlier (Race et al,
2007). To confirm the identity of the products, their absorbance
was monitored simultaneously at four different wavelengths (246,
260, 310 and 397 nm) each at or close to absorbance maxima for
one or more product. The amount of 2- and 4-hydroxylamine
products isolated using this system was determined from the
peak areas of the chromatogram, using e260 nm¼ 7880 M1cm1 for
the 4-hydroxylamine and e260 nm¼ 5420 M1cm1 for the 2-hydroxyl-
amine (Knox et al, 1991).
For the analysis of cellular metabolites of CB1954, single cell
suspensions of SKOV3-GFP, SKOV3-NfsB and SKOV3-NfsA stable
cell lines were generated from log phase monolayer cultures and
stirred magnetically at 5 105 cells per ml in an aMEM culture
medium (Sigma-Aldrich Co. Ltd, Gillingham, UK) without serum
and supplemented with additional ascorbate (50 mg ml1) to
prevent the auto-oxidation of the hydroxylamine metabolites.
After equilibration, CB1954 was added to a final concentration of
10 or 100 mM. Samples (300ml) were removed at various time points
up to 3 h, centrifuged rapidly and the extracellular medium was
stored at 801C until analysed by HPLC using detection at 254 nm
(peak identity confirmed by reference to authentic standards) or
by LC/MS (4-amine metabolite, detected using negative mode
atmospheric pressure chemical ionisation at m/z 221) as described
(Helsby et al, 2004).
Sensitisation of SKOV3 cells to CB1954 using purified
enzymes
SKOV3 human ovarian carcinoma cells were seeded at a density of
10 000 cells per well in 96-well plates, in Dulbecco’s Modified
Eagle’s Medium (Sigma-Aldrich Co. Ltd) (HEPES buffered) with
10% foetal calf serum, and incubated at 371C in 5% CO2. After 2
days, the medium was removed from the wells and replaced with
50ml of serum-free medium containing 100 nM FMN and various
concentrations of purified NfsA or NfsB, to which was added 100 ml
of serum-free medium containing CB1954 and cofactor (NADH or
NADPH), to give final concentrations of 0.1– 100 nM enzyme, 50mM
CB1954 and 200 mM cofactor. The cultures were incubated for 4 h at
371C before the prodrug-containing medium was replaced with
fresh, complete medium. The relative number of viable cells was
determined after a further 2 days using the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Mosmann,
1983). Absorbances at 490 nm were read on a Wallac Victor 2 1420
Multilabel Counter (Perkin-Elmer, Fremont, CA, USA), normalised
relative to 100% survival of cells in wells with no added enzyme.
Sigmoid curves were fitted, and F-tests performed to determine the
statistical significance of differences between the curves, using
Graphpad Prism software (GraphPad Software Inc., La Jolla, CA,
USA).
Eukaryotic expression: retroviral vectors
The retrovirally transduced SKOV-NTR cell line, which stably
expresses NfsB, was described earlier (McNeish et al, 1998). For
clarity in this report, SKOV-NTR cells are referred to as SKOV3-
NfsB.
The nfsA gene was amplified by PCR from E. coli DH5a genomic
DNA using primers PS1296A GCCGCCACCATGACGCCAACC
ATTGAACTTATTTGTG and PS1296D, and inserted into the
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Hpa I site downstream of the CMV promoter in the retroviral
vector plasmid pxLNCX (Green et al, 1997) to generate pSV035.
The retrovirus packaging cell line, FLYA13, (Cosset et al, 1995) was
transfected with pSV035 using calcium phosphate (Graham and
van der Eb, 1973), and retrovirus producer cells were selected
using G418 (500mg ml1). The supernatant from these cells was
filtered (0.45 mm) and added with 8 mg ml1 of polybrene
(Sigma-Aldrich Co. Ltd) to SKOV3 ovarian carcinoma cells, which
were subsequently selected using G418 (500 mg ml1). Clonal cell
lines were generated by limiting dilution; SKOV3-NfsA clone 4 was
found to have a CB1954 sensitivity very close to that of SKOV3-
NfsB, and was chosen for further experiments. As a negative
control, a clone of SKOV3 cells (SKOV3-GFP) was generated with a
similar vector expressing enhanced green fluorescent protein
(EGFP).
Adenovirus vectors
The E1-, E3-deleted, replication-defective adenovirus CTL102,
which expresses NfsB from the CMV promoter, was described
earlier (Djeha et al, 2001). An equivalent adenovirus AdSV042
expressing NfsA was generated similarly, using the Bam HI
fragment containing the CMV promoter and the nfsA gene from
pSV035, inserted into the E1 deletion. Transfection, two rounds of
plaque purification, and subsequent virus expansion used 911 cells
(Fallaux et al, 1996). Virus was purified by CsCl banding, viral
particle concentration was determined by DNA assay using
Picogreen (Invitrogen, Paisley, UK), and infectious titre
(p.f.u. ml1) was determined using a plaque assay on 911 cells.
Cytotoxicity assays
SKOV3 cells were infected in suspension with the adenovirus
vectors at multiplicities from 30 to 300 p.f.u. per cell for 90 min,
before plating 1 104 cells per well in 96-well plates. After 2 days,
the medium was replaced with fresh medium containing prodrug
at a range of concentrations. Triplicate wells were used for each
condition. The prodrug was removed after 4 h incubation at 371C
and replaced with fresh medium. Cell survival was determined
using the MTT assay 48 h later (Mosmann, 1983). Absorbances
were read on a Victor plate reader, normalised relative to 100%
survival of cells not exposed to prodrug, and sigmoid curves were
fitted, and the significance of differences between the curves was
determined by the F-test, using the Graphpad Prism software.
To determine the bystander effect with NfsA vs NfsB, SKOV3-
NfsA or SKOV3-NfsB cells were mixed with SKOV3 cells at
proportions of 100, 50, 25, 12.5, 6.25, 3.13, 1.56 and 0%, and plated
at a total of 2 104 cells per well in 96-well plates. After 1 day, the
cell mixtures were exposed to a range of CB1954 concentrations in
triplicate, for 18 h. Cell survival was assayed using the MTT assay
48 h later.
Comparison of the cytotoxicity of DNBM prodrugs with SKOV3-
NfsA and SKOV3-NfsB cells used 6 103 cells per well plated the
day before the addition of prodrug. The medium was replaced after
4 h of prodrug exposure, and the relative cell number was
determined 4 days after the addition of prodrug by staining with
sulphorhodamine B (Skehan et al, 1990).
RESULTS
Sensitisation of E. coli to CB1954 by overexpression of
NfsA nitroreductase
We inserted nfsA into a bacteriophage l-vector under the control
of the IPTG-inducible tac promoter and generated E. coli lysogens,
in which a single copy of the bacteriophage genome was inserted
into the bacterial chromosome. The expression of NfsB in this
system sensitises the bacteria to CB1954, resulting in the inhibition
of colony formation when the bacteria are plated on agar containing
CB1954. The reduction in plating efficiency depends both on the
concentration of CB1954 and on the activity of the expressed
enzyme with the prodrug (Grove et al, 2003; Guise et al, 2007).
As shown in Figure 1, bacterial lysogens carrying the empty
vector (lJG3J1) showed no reduction in plating efficiency at
CB1954 concentrations up to 300 mM, indicating that the expression
levels of endogenous NfsA or other enzymes do not confer
significant sensitisation to the prodrug over this range. Lysogens
carrying the vector lJG16C2, which expresses NfsB, showed
complete inhibition of colony formation at 300 and 200mM
CB1954, but at 100 mM CB1954 and below the plating efficiency
was X80%. Bacteria carrying lSV054, expressing NfsA, showed
greater sensitisation to CB1954, with complete inhibition of colony
formation at X100 mM CB1954, implying that NfsA catalyses the
activation of CB1954 more efficiently than does NfsB.
In vitro kinetics of NfsA and NfsB with CB1954
Figure 2 compares the rates of CB1954 activation by purified NfsA
and NfsB as a function of CB1954 concentration, using either
NADH or NADPH as a cofactor. In agreement with earlier work
(Zenno et al, 1996), NfsA has a higher catalytic activity with
NADPH than with NADH. At 50 mM cofactor, this results in B8-
fold higher maximum rate of CB1954 activation with NADPH
(Figure 2A). For NfsB, there is a small preference for NADH over
NADPH, with ao2-fold difference in the rate of CB1954 activation
for the two cofactors over the achievable solubility range of
CB1954 (Figure 2B, solid lines). With its preferred cofactor
NADPH, NfsA shows a much greater efficiency of CB1954
activation than NfsB, as shown by the dotted curve in Figure 2B.
At the low substrate concentrations achievable in vivo (o10 mM),
the rate of reaction is proportional to kcat/Km; for NfsA this is
B25-fold higher than for NfsB (see Table 1).
Owing to solubility limits of CB1954 in an aqueous solution, 5%
DMSO was included in the reaction buffer to achieve CB1954
concentrations 41 mM. In separate experiments using 100mM
CB1954, 5% DMSO was found to slow the rate at which NfsA
and NfsB reduced CB1954 by 10 and 35%, respectively. Thus, the
data of Figure 2 and Table 1 may overestimate the kinetic
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Figure 1 Sensitisation of Escherichia coli to CB1954 by the expression
of NfsA or NfsB. Log phase cultures of E. coli UT5600 stably lysogenised
with bacteriophage l-vectors expressing NfsA or NfsB, or empty vector
as control, were diluted and plated on agar containing 0, 50, 100, 200 or
300 mM CB1954. Colonies were counted after 24 h, and expressed as a
percentage (%) of the number obtained from the same liquid culture plated
in the absence of a prodrug (mean and range of duplicates).
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advantage of NfsA by a factor of B1.4; nevertheless, this still
implies that NfsA will activate CB1954 B18-fold faster than NfsB
in physiological conditions.
Increased sensitisation of human carcinoma cells to
CB1954 by NfsA nitroreductase
To compare the relative potency of NfsA and NfsB for sensitising
human cancer cells with CB1954, we incubated SKOV3 ovarian
carcinoma cells for 4 h with 50 mM CB1954 and either NADH
or NADPH (200 mM), together with a range of concentrations of
the purified enzymes. Cell viability was measured 2 days later. As
shown in Figure 3A, at 100 nM, either of the enzymes with either
cofactor could activate sufficient CB1954 to kill all the cells, but
below 10 nM enzyme, only NfsA achieved significant toxicity, and
that required NADPH as a cofactor. Sigmoid curves fitted to the
data indicate that a 50% reduction in cell viability would require
just 0.69 nM NfsA (95% CI: 0.62–0.77) when used with NADPH,
whereas equivalent cell killing requires 15.7 nM NfsB (with NADH;
95% CI: 14.3– 17.3) or 20.8 nM NfsB (with NADPH, 95% CI: 19.1–
22.7). As indicated by the kinetic studies, NfsA was much less
effective with the NADH cofactor, requiring 26.3 nM enzyme (95%
CI: 24.9–27.7) to kill half the cells. The accuracy of the enzyme
concentrations was confirmed by running 200 and 50 ng of each
enzyme on a SDS-polyacrylamide gel, which was stained with
Coomassie blue (Sigma-Aldrich Co. Ltd) (Figure 3B). Thus, these
data confirm that NfsA could be up to 20-fold more effective than
NfsB for prodrug activation gene therapy with CB1954, although
clearly the actual benefit will depend on the relative availability of
the reduced cofactors in the cell.
To investigate cell sensitisation to CB1954 by intracellularly
expressed enzymes, we constructed a replication-defective adeno-
virus (AdSV042) expressing NfsA nitroreductase from the CMV
promoter, and compared this with the similar NfsB-expressing
virus, CTL102 (Djeha et al, 2001). SKOV3 ovarian carcinoma cells
were infected with 30, 100 or 300 p.f.u. per cell of the two viruses,
or mock-infected, and after 2 days, the cultures were exposed to a
range of CB1954 concentrations for 4 h. Dose-response curves
showing the effect of CB1954 on cell viability 2 days later are
shown in Figure 3C. Mock-infected cells showed no reduction in
viability even with 1000mM CB1954, whereas cells infected with the
nitroreductase-expressing adenoviruses were sensitised to pro-
drug. As expected, greater sensitisation was achieved by higher
multiplicity of infection (MOI) of the viruses. At each MOI, greater
sensitisation was achieved by the virus expressing NfsA. For
example, the IC50 (prodrug concentration required to reduce viable
cell number to 50%) for cells infected with 300 p.f.u. per cell
AdSV042 was 13.5mM (95% CI: 13.0–14.0), whereas that obtained
with 300 p.f.u. per cell CTL102 was 86.6mM (95% CI: 82.9– 90.6),
corresponding to a 6.3-fold greater sensitisation by the virus
expressing NfsA (Po0.0001). In other similar experiments, the
benefit of expressing NfsA rather than NfsB by the virus at this
MOI ranged from 3.5 to 8.1 fold. To determine the proportion of
SKOV3 cells infected by adenovirus vectors at these MOI, we used
a similar adenovirus expressing enhanced green fluorescent
protein (Ad-EGFP), and analysed the infected cell population by
flow cytometry (data not shown). Two days after infection with
300 p.f.u. per cell, 99% of the infected cell population expressed
detectable EGFP, indicating that the prodrug-dependent cytotoxi-
city achieved with this MOI of the NfsA- or NfsB-expressing
viruses can be attributed to the expression of the enzymes in
almost every cell. Infection with 100 or 30 p.f.u. per cell Ad-EGFP
resulted in 87 and 52% EGFP-positive cells, respectively. Thus, the
ability of higher concentrations of CB1954 to kill more than 87
or 52% of the cells infected with 100 or 30 p.f.u. per cell of the
nitroreductase-expressing viruses is indicative of bystander
cytotoxicity, attributable to the escape of activated prodrug from
nitroreductase-expressing cells.
Metabolite analysis of CB1954 after activation by NfsA
nitroreductase
In the past, NfsB nitroreductase was shown to reduce either of the
two nitro groups of CB1954 to the hydroxylamines, in equal
proportions (Knox et al, 1992; Race et al, 2007); greater cyto-
toxicity was reported for the 4-NHOH derivative in DNA repair-
deficient hamster cell lines (Knox et al, 1988, 1991; Helsby et al,
2003), although for a number of human cancer cell lines, both the
4-NHOH and 2-NHOH (and derived 2-NH2) products were
reported to have similar cytotoxicity (Helsby et al, 2004). We
v/
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Figure 2 In vitro kinetics of CB1954 activation by purified NfsA and NfsB, using NADH or NADPH as cofactors. Graphs plot initial rate of CB1954
activation (v) normalised by enzyme concentration (E), using 50 mM NAD(P)H at a range of CB1954 concentrations, with Michaelis –Menten curves fitted to
the data. (A) Kinetics of NfsA. (B) Kinetics of NfsB (solid lines); for comparison, the dotted line again shows the kinetics of NfsA using NADPH.
Table 1 Kinetic parameters for reduction of CB1954 by NfsA or NfsB,
using 50 mM NADH or NADPH as a cofactor
Enzyme Cofactor kcatAPP (s
1)a KmAPP (lM)
a kcat/Km (lM
1s1)
NfsA NADPH 20.9±0.7 140±15 0.15±0.01
NfsA NADH 2.60±0.08 18±3 0.15±0.02
NfsB NADPH 15±1 2600±400 0.0058±0.0004
NfsB NADH 50±20 8000±5000 0.006±0.001
akcatAPP and KmAPP are the apparent rate constant kcat and Michaelis constant Km,
using the indicated cofactor at 50 mM concentration; best fit parameters (±s.e.)
derived by non-linear regression to Michaelis –Menten curves.
NfsA nitroreductase for CB1954 prodrug activation
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used HPLC to compare the products of CB1954 reduction by NfsA
and NfsB, both with purified enzymes and in cells. Supplementary
Figure 1 shows the products of reduction of CB1954 by the purified
enzymes. Purified NfsB generated equal amounts of the 2-NHOH
and 4-NHOH products from CB1954, whereas NfsA only generated
significant amounts of the 2-NHOH species; no other reduction
products were observed.
To compare the prodrug activation products generated by the
enzymes in the intracellular environment, the metabolites released
to the medium by SKOV3 cells stably expressing NfsA or NfsB, or
control cells (expressing GFP) were examined at different times
after the addition of CB1954 (Figures 4A, C and E). Figures 4B, D
and F show HPLC traces corresponding to the 2 h time point. The
HPLC profiles show some peaks in addition to CB1954 (from
media components) present in the supernatant of the control,
GFP-expressing cells (Figure 4B). However, there was no reduction
in the CB1954 peak during the incubation, and no metabolites of
CB1954 were detected in the supernatant from SKOV3-GFP cells
(Figure 4A). Two additional major peaks were produced in the
medium from SKOV3-NfsA cells (Figure 4D), corresponding to the
2-NHOH and 2-NH2 derivatives of CB1954. As shown in the time
course (Figure 4C), accumulation of the 2-NH2 species in
supernatant of SKOV3-NfsA cells lags behind that of the 2-NHOH,
as expected for a further reduction product from the hydro-
xylamine. As the amine metabolites of CB1954 are not detected
after reduction by purified NfsA or NfsB, they may result from the
action of cellular enzymes on the hydroxylamine products initially
generated by NfsA or NfsB. Relatively little of the 4-NHOH and
derived 4-NH2 species were detectable with SKOV3-NfsA cells; the
2-NO2 reduction products were in 25- to 40-fold excess over the
products of 4-NO2 reduction (at 30 min to 2 h). In contrast, with
cells expressing NfsB, the levels of 2-NO2 and 4-NO2 reduction
products were more similar (only B1.7- to 1.8-fold excess of
2-NO2 metabolites, at 1 –2 h) (Figures 4E, F). The departure from a
1 : 1 ratio of 2-NO2 and 4-NO2 reduction products released to the
medium by SKOV3-NfsB cells may be attributable to greater
reactivity of the 4-NHOH species inside the cell. Metabolite ratios
were similar in a separate experiment using a more pharmacolo-
gically relevant CB1954 concentration (10 mM), which confirmed
the preference of NfsA for the reduction of the 2-NO2 group (data
not shown). Thus, in cells and with the purified enzyme, NfsA
shows a strong bias towards reduction of the 2-NO2 group of
CB1954.
Bystander effect of NfsA nitroreductase
Helsby et al (2004) suggested that the bystander effect from the
activation of CB1954 is largely caused by the 2-NHOH and derived
2-NH2 metabolites, rather than the 4-NHOH product. Because
NfsA nitroreductase preferentially reduces the 2-NO2 group of
CB1954 as shown above, we anticipated that it might produce a
greater bystander effect than NfsB nitroreductase. The stably
transduced cell lines, SKOV3-NfsA and SKOV3-NfsB, are closely
matched for sensitivity to CB1954 (as shown in Figure 5A and
Table 2), facilitating comparison of the bystander effect
with the two enzymes. Untransduced ‘target’ SKOV3 cells and
transduced ‘activator’ (SKOV3-NfsA or SKOV3-NfsB) cells were
mixed in various proportions before testing the susceptibility of
the mixed cultures to CB1954. Figure 5A shows a selection of the
dose-response curves for cell survival in the mixed cultures. The
IC50 (CB1954 concentration giving 50% reduction in viable cells)
for SKOV3 cells alone was 400 mM CB1954, whereas IC50s for
cultures of 100% SKOV3-NfsA or SKOV3-NfsB were B0.6mM
CB1954. The mixed cell populations showed CB1954 dose-response
curves and IC50s intermediate between those of pure activator and
pure target cells, depending on the proportion of activator cells
and the enzyme (NfsA or NfsB). The IC50s for all cell mixtures, and
the unmixed cells, are plotted against percentage activator cells in
Figure 5B. The IC50s for mixtures with SKOV3-NfsA cells are lower
than for mixtures of SKOV3-NfsB cells over the entire range from
1.56 to 50% activator cells. For mixtures containing between 3.12
and 25% activator cells, this advantage equates to a three- to five-
fold lower IC50 when using NfsA. Conversely, if we consider the
proportion of activator cells required to achieve an IC50 of 15mM
CB1954 (midway on a log scale between the IC50 of SKOV3 cells
and either activator cell type), this would require 13.7% of SKOV3-
NfsB cells, but only 5.7% of SKOV3-NfsA cells (Po0.01).
Comparison of NfsA and NfsB nitroreductase for
activation of alternative prodrugs
The nfsA and nfsB genes were originally identified through their
role in sensitising bacteria to the nitrofuran antibiotics, nitro-
furazone and nitrofurantoin. NfsB has been shown to sensitise
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Figure 3 Sensitisation of human ovarian carcinoma cells to CB1954 by
NfsA or NfsB. (A) SKOV3 cells were incubated in a medium containing
50mM CB1954, 200 mM NADH or NADPH and a range of concentrations
of purified NfsA or NfsB proteins. The components were mixed at the start
of a 4-h incubation period at 371C, after which the medium was changed.
Cell viability was determined 2 days later using the MTT assay. One
representative experiment of three is shown. (B) To confirm the enzyme
concentrations used in panel A, 200 and 50 ng of the purified proteins were
analysed by SDS-PAGE and stained with Coomassie blue. (C) SKOV3 cells
were infected using 0, 30, 100 or 300 p.f.u. per cell of adenovirus vectors
CTL102 or AdSV042, expressing NfsB or NfsA, respectively. After 2 days,
they were exposed to a range of CB1954 concentrations for 4 h, before
determination of cell viability using MTT assay 2 days later. (The values used
are representative of at least three experiments.)
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human cells to nitrofurazone (Bailey et al, 1996). We compared the
two enzymes using SKOV3 cells infected with 50 p.f.u. per cell of
CTL102 or AdSV042. Mock-infected cells had IC50s of 410 and
520mM nitrofurazone and nitrofurantoin, respectively. The expres-
sion of NfsB by CTL102 resulted in 23- and 17-fold sensitisation,
respectively, whereas that of NfsA by AdSV042 caused 71- and
34-fold sensitisation, indicating that NfsA is approximately three-
and two-fold better than NfsB for cell sensitisation to nitro-
furazone and nitrofurantoin, respectively. However, in cell mixing
experiments, neither of these prodrugs gave detectable bystander
cell killing, using either NfsA or NfsB (data not shown).
The DNBMs are another promising class of prodrug activated by
NfsB (Anlezark et al, 1995; Wilson et al, 2002). We evaluated the
ability of NfsA to activate three representative DNBM prodrugs
using the SKOV3-NfsA and SKOV3-NfsB cell lines. As shown in
Table 2, although these cell lines were matched for equal sensitivity
to CB1954, the IC50s for all three DNBM prodrugs were B1.8- to
2.8-fold lower for SKOV3-NfsA than for SKOV3-NfsB cells,
indicating that NfsA also activates this family of prodrugs more
efficiently than NfsB.
DISCUSSION
We have shown that NfsA nitroreductase can activate CB1954
significantly faster than NfsB at low substrate concentrations when
using the NADPH cofactor, and that it selectively reduces the
2-NO2 rather than the 4-NO2 group (whereas NfsB shows no
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Figure 4 HPLC analysis of time course and regiospecificity of CB1954 reduction by SKOV3 cells expressing NfsA or NfsB. (A, C, E) Time courses of
CB1954 reduction and accumulation of CB1954 metabolites in extracellular medium (mean and s.e.m of three experiments; key in panel A also applies for
panels C and E); no metabolites of CB1954 were detected using SKOV3-GFP cells (panel A). (B, D, F) HPLC traces of medium sampled after 2 h
incubation. Peaks marked C and P correspond to CB1954 and phenol red; peaks marked 2 and 4 correspond to the 2-NHOH and 4-NHOH products and
those marked 20 and 40 indicate the corresponding -NH2 metabolites. Panels A and B represent SKOV3-GFP cells (control); panels C and D represent
SKOV3-NfsA cells; and panels E and F represent SKOV3-NfsB cells.
NfsA nitroreductase for CB1954 prodrug activation
SO Vass et al
1908
British Journal of Cancer (2009) 100(12), 1903 – 1911 & 2009 Cancer Research UK
T
ra
n
sla
tio
n
a
l
T
h
e
ra
p
e
u
tic
s
preference). The improved kinetics may result from the more open
active site of NfsA (Kobori et al, 2001; Lovering et al, 2001), in
particular, the absence of any amino acids in NfsA at a position
corresponding to the residue Phe124 of NfsB, mutation of which to
a wide variety of alternative residues improved the rate of CB1954
activation (Grove et al, 2003). However, a more detailed
explanation of the differences in substrate binding, in particular
to explain the regioselectivity of CB1954 activation by NfsA, will
require further studies. We have identified two explanations
regarding why the initial purification and cloning of an enzyme
capable of CB1954 activation from E. coli isolated NfsB rather than
NfsA (Anlezark et al, 1992). First, the assay used to monitor
purification used the cofactor NADH, whereas NfsA has a strong
preference for NADPH (see Figure 2) (Bryant et al, 1981; Zenno
et al, 1996); furthermore, this assay used menadione as a substrate,
which is reduced about twice as efficiently by NfsB as by NfsA
(Zenno et al, 1996). Although the initial demonstration that NfsB
could activate CB1954 (and does so B90-fold faster than rat
DT-diaphorase (Anlezark et al, 1992)) led to the adoption of
NfsB for prodrug activation gene therapy with CB1954, this
paper presents evidence based on cell cultures that it may be
advantageous to use NfsA in preference.
For an enzyme reaction at substrate concentrations far below the
Km will be the case with either NfsA or NfsB at the concentrations
of CB1954 achievable in patients (o10 mM (Chung-Faye et al,
2001)), the rate of reaction is proportional to kcat/Km. With
purified enzymes in vitro, this ratio was 25-fold higher for NfsA
than for NfsB; taking into account a modest differential inhibition
of the two enzymes by DMSO in the reaction buffer, the data
indicated that NfsA isB18-fold more efficient at reducing CB1954.
In agreement with this, when using the NADPH cofactor, purified
NfsA was B20-fold more potent than NfsB (with either cofactor)
for sensitising SKOV3 ovarian carcinoma cells to CB1954. The
relative rates of CB1954 activation by NfsA and NfsB expressed
within cells will depend on the intracellular concentrations of
NADH and NADPH. The maximum benefit of NfsA would occur if
the intracellular NADPH concentration greatly exceeded that of
NADH; conversely as indicated by Figure 3A, a preponderance of
NADH would favour NfsB. We could find very few reports of
cofactor concentrations in cells or tissues; one study measured
approximately 15–44 mM NADPH in three B-cell lines (Hancock
et al, 1989), and HPLC analysis of HEK293 cells (adenovirus-
transformed human embryonic kidney cells) showed NADH levels
that appeared approximately 1– 2 times greater than NADPH
(Pollak et al, 2007). To compare cancer cell sensitisation with
CB1954 by the enzymes after gene transfer, we used replication-
defective adenoviruses AdSV042 (expressing NfsA) compared with
the similar adenovirus, CTL102 (expressing NfsB). In three
experiments, the adenovirus expressing NfsA achieved B3.5-,
6.3- and 8.1-fold lower IC50 than that expressing NfsB (compar-
isons at 300 p.f.u. per cell; Po0.001 for all differences). In the
absence of available antibodies capable of detecting NfsA, we
cannot independently confirm that NfsA and NfsB are expressed at
equal levels in the target cells; however, as they were delivered and
expressed by the otherwise identical adenovirus vectors, these
experiments provide a fair indication of their relative potential
benefit for prodrug activation gene therapy. The reduced benefit
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Figure 5 Bystander effect with NfsA vs NfsB. (A) ‘Activator cells’, that is,
SKOV3 cells stably expressing either NfsA or NfsB, parental SKOV3 cells
and cell mixtures containing 50, 25, 12.5, 6.25, 3.12 and 1.56% of the
activator cells mixed with SKOV3 target cells, were exposed to a range of
CB1954 concentrations, and their subsequent survival determined using
the MTT assay; symbols show the mean and range of duplicate wells. For
clarity, only dose-response curves for 25 and 6.25% activator cells are
shown. (B) The IC50s (±95% CI), derived from the MTT assay cell survival
curves in panel A are plotted against percentage (%) activator cells in the
mixture. The horizontal lines indicate the IC50s of parental SKOV3 cells
(upper line), pure cultures of SKOV3-NfsA and SKOV3-NfsB (lower line),
and the prodrug concentration midway between these on a log scale.
Table 2 Improved cell sensitization to DNBM prodrugs using NfsA vs
NfsB
CB1954 SN24927 SN26209 SN27653
aSKOV3-GFP
IC50 (mM)
1910±171 489b 46.9±5.6 165±20
aSKOV3-NfsA
IC50 (mM)
1.33±0.09 0.42±0.05 0.14±0.04 1.00±0.11
aSKOV3-NfsB
IC50 (mM)
1.33±0.08 0.76±0.15 0.29±0.10 2.85±0.60
cIC50 ratio
(NfsB/NfsA)
1.02±0.13 1.81±0.19* 2.02±0.37* 2.81±0.36**
Prodrug structures
aSKOV3-GFP, SKOV3-NfsA and SKOV3-NfsB cells were compared for sensitivity
with CB1954 and three DNBM prodrugs, using 4 h exposure, in three separate
experiments; the mean IC50 is shown ±s.e.m.
bIC50 was beyond the tested range
(4100mM) in two of three experiments. cThe IC50 ratio was determined separately
in each experiment; the table shows the mean and s.e.m. of these ratios. In each
experiment, the dose-response curves for SKOV3-NfsA and SKOV3-NfsB cells were
compared by F-test; the statistical significance indicated (*Po0.05; **Po0.01)
represents the largest P-value from the three experiments.
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observed with intracellularly expressed NfsA, compared with
extracellular enzymes with added NADPH, might be explained by
the available concentrations of NADH and NADPH within the cells.
We observed that NfsA preferentially reduces the 2-NO2 rather
than the 4-NO2 group of CB1954 to the hydroxylamine (NHOH),
whereas NfsB generates equal amounts of the 2-NHOH and
4-NHOH products. Studies of the diffusion properties of
CB1954 metabolites through multicellular layers (Helsby et al,
2004) suggested that the 2-NO2 reduction products should be more
effective at bystander cell killing. In cell mixing experiments
with various proportions of ‘activator’ cells expressing NfsA or
NfsB, we confirmed that the expression of NfsA conferred a greater
bystander effect with CB1954 than was obtained with NfsB.
We have also shown that expressing NfsA rather than NfsB from
an adenovirus vector is more efficient for sensitising human cells
to nitrofurazone and nitrofurantoin. Although the therapeutic
index of these nitrofuran antibiotics is lower than for CB1954, they
have the advantage of established high clinical tolerability. The
lack of significant bystander cell killing with these prodrugs would
limit their utility for GDEPT. Nevertheless, NfsA may be useful for
cell sensitisation to nitrofurazone or nitrofurantoin, for applica-
tions in which bystander cell killing may be undesirable—for
example, ablation of adoptively transferred cells or selective cell or
tissue ablation in transgenic animals (Isles et al, 2001).
Another promising class of alternative prodrugs activated by
NfsB are the DNBMs (Anlezark et al, 1995; Atwell et al, 2007).
SN24927 is the bromo-analogue of SN23862, the most studied
alternative prodrug to CB1954 for use in combination with NfsB
nitroreductase (Helsby et al, 2004). Earlier studies using
NfsB expression to activate the 2,4-dinitrobenzamide-5-mustard,
SN24927, showed a greater bystander effect than with CB1954, and
superior anti-tumour activity in mice (Wilson et al, 2002; Atwell
et al, 2007). A 3,5-dinitrobenzamide-2-mustard closely related
to SN26209 (Table 2) has been shown recently to be a potent
NfsB prodrug (Singleton et al, 2007). All DNBM prodrugs require
reduction of the nitro group para to the mustard for activation;
this is equivalent to the 2-NO2 group of CB1954, which we have
shown to be preferentially reduced by NfsA. Using SKOV3 cells
expressing NfsA or NfsB and matched for sensitivity to CB1954, we
found that the SKOV3-NfsA cells were 1.8- to 2.8-fold more
sensitive to the DNBM prodrugs than SKOV3-NfsB, indicating that
the benefit of using NfsA rather than NfsB to activate these
prodrugs is greater than with CB1954.
An earlier screen of different bacteria for nitroreductases
suitable for prodrug activation therapies identified YwrO from
Bacillus amyloliquefaciens, which selectively reduces the 4-NO2
group of CB1954 and was reported to have a modest kinetic
advantage relative to E. coli NfsB (Anlezark et al, 2002). However,
YwrO seemed markedly less effective than NfsB at sensitising V79
hamster cells to CB1954, and was unable to activate the DNBM
prodrug SN23862. Another enzyme from E. coli, YieF, was shown
to be comparable with NfsA for sensitising human cells to CB1954,
although neither was compared with NfsB (Barak et al, 2006). As
the cytotoxicity of at least the 4-hydroxylamino derivative of
CB1954 was proposed to require acetylation (Knox et al, 1991), the
possible benefit of co-expressing acetyl transferases with NfsB has
been tested. Co-expression of human N-acetyl transferase-2 was
shown to significantly enhance the sensitisation of NfsB-expres-
sing cells to CB1954 (Mitchell and Minchin, 2008); however, the
bystander effect was concomitantly reduced.
The 3.5- to 8.1-fold improvement in the sensitisation of human
cells to CB1954 by adenovirus vectors expressing NfsA relative to
NfsB is similar to the level of improvement that has been achieved
by the best single amino acid substitutions within the active site
of NfsB (Grove et al, 2003). Further multiple-substitution mutants
of NfsB further optimised for CB1954 activation have been
selected (Guise et al, 2007), and mutants of YieF showing improved
sensitisation to CB1954 relative to NfsA were reported (Barak et al,
2006). Nevertheless, the observed improvement in bystander cell
killing attributable to preferential reduction of the 2-NO2 group of
CB1954 by NfsA is a desirable feature, suggesting that NfsA could
itself be a good starting enzyme for further mutagenic enhance-
ment of its catalytic rate. This regioselectivity of nitroreduction by
NfsA is also reflected in its improved cell sensitisation to DNBM
prodrugs relative to NfsB. We conclude that NfsA should be
considered as an alternative prodrug-activating enzyme to NfsB for
use in prodrug activation gene therapy or cell/tissue ablation
studies using CB1954, nitrofuran antibiotics or DNBM prodrugs.
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